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Abstract
AIM
To develop a prognostic scoring system for overall 
survival (OS) of patients undergoing liver resection (LR) 
for hepatocellular carcinoma (HCC).
METHODS
Consecutive patients who underwent curative LR for 
HCC between 2000 and 2013 were identified. The series 
was randomly divided into a training and a validation 
set. A multivariable Cox model for OS was fitted to the 
training set. The beta coefficients derived from the Cox 
model were used to define a prognostic scoring system 
for OS. The survival stratification was then tested, 
and the prognostic scoring system was compared with 
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ORIGINAL ARTICLE
Development of a prognostic scoring system for resectable 
hepatocellular carcinoma
Retrospective Study
Carlo Sposito, Stefano Di Sandro, Federica Brunero, Vincenzo Buscemi, Carlo Battiston, Andrea Lauterio, 
Marco Bongini, Luciano De Carlis, Vincenzo Mazzaferro
the European Association for the Study of the Liver 
(EASL)/American Association for the Study of Liver 
Diseases (AASLD) surgical criteria by means of Harrell’s 
C statistics.
RESULTS
A total of 917 patients were considered. Five variables 
independently correlated with post-LR survival: Model 
for End-stage Liver Disease score, hepatitis C virus 
infection, number of nodules, largest diameter and 
vascular invasion. Three risk classes were identified, 
and OS for the three risk classes was significantly 
different both in the training (P  < 0.0001) and the 
validation set (P  = 0.0002). Overall, 69.4% of patients 
were in the low-risk class, whereas only 37.8% were 
eligible to surgery according to EASL/AASLD. Survival 
of patients in the low-risk class was not significantly 
different compared with surgical indication for EASL/
AASLD guidelines (77.2 mo vs  82.5 mo respectively, P  
= 0.22). Comparison of Harrell’s C statistics revealed 
no significant difference in predictive power between 
the two systems (-0.00999, P  = 0.667).
CONCLUSION
This study established a new prognostic scoring system 
that may stratify HCC patients suitable for surgery, 
expanding surgical eligibility with respect to EASL/
AASLD criteria with no harm on survival.
Key words: Hepatocellular carcinoma; Liver resection; 
Liver cirrhosis; Prognosis; Survival study
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: European Association for the Study of the 
Liver (EASL)/American Association for the Study of Liver 
Diseases (AASLD) guidelines recommend liver resection 
(LR) for hepatocellular carcinoma (HCC) only for single 
nodules of any size in patients without tumor related 
symptoms, no clinically significant portal hypertension 
and normal bilirubin. In this study we investigated the 
prognostic factors for survival of patients who under-
went LR for HCC. We built a prognostic scoring system 
to stratify post-resection prognosis, and we identified a 
larger subset of patients with an expected survival that 
equates that of patients undergoing LR according to 
guidelines. Thus, the current EASL/AASLD indications 
for LR can be safely expanded, with no detrimental 
effect on patients’ prognosis.
Sposito C, Di Sandro S, Brunero F, Buscemi V, Battiston C, 
Lauterio A, Bongini M, De Carlis L, Mazzaferro V. Development 
of a prognostic scoring system for resectable hepatocellular 
carcinoma. World J Gastroenterol 2016; 22(36): 8194-8202 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v22/i36/8194.htm  DOI: http://dx.doi.org/10.3748/wjg.v22.
i36.8194
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most frequent 
primary tumor of the liver, and it is the third cause of 
cancer death worldwide[1]. Most HCC cases (from 65% 
to 90%) occur in the context of chronic hepatitis and 
cirrhosis[2], which are attributable mainly to chronic 
hepatitis B virus or hepatitis C virus (HCV) infections, 
followed by chronic alcohol abuse, obesity and diabe­
tes[3]. The estimated rate of each of these risk factors 
varies depending on the different regions of the world.
The prognosis of patients with HCC and the choice 
among the available therapeutic options, largely dep­
ends on tumor extension and underlying liver function. 
According to the European Association for the Study 
of the Liver (EASL)[4] and the American Association 
for the Study of Liver Diseases (AASLD)[5] guidelines, 
treatment allocation is routed by the Barcelona Clinic 
Liver Cancer staging system (BCLC)[6]. In particular 
liver resection (LR) is considered as the first­line 
treatment only for patients at an early stage of the 
disease, namely those with an optimal liver function 
(Child­Pugh A, normal bilirubin and absence of clinically 
relevant portal hypertension), a preserved physical 
condition (ECOG Performance Status of 0), and a 
single tumor nodule with no evidence of extra­hepatic 
spread nor involvement of major vascular structures. 
In this subset of optimal patients, a 5­year overall 
survival (OS) of approximately 70% may be expected, 
similar to that of liver transplantation[7]. Several field 
practice studies have ascertained that LR is often 
offered outside these conventional indications, and 
various authors reported acceptable survival rates 
for patients with HCC resected at a more advanced 
stage because of macrovascular invasion[8,9], multiple 
nodules or impaired liver function[10,11]. In addition, 
more recent studies demonstrate a survival benefit of 
radical surgery with respect to the available treatment 
alternatives across the different BCLC stages[12­14].
The objective of this study is to investigate the 
prognostic factors for survival of patients who under­
went LR for HCC at two referral centers ­ in which the 
surgical indication was not restricted to the current 
guidelines ­ and to build a prognostic scoring system 
to stratify post­treatment prognosis and possibly to 
expand the actual western indications to LR without 
harmful adverse outcomes.
MATERIALS AND METHODS
From January 2000 to March 2013 data from all pat­
ients who underwent a curative LR for HCC at the 
Departments of Gastrointestinal Surgery and Liver 
Transplantation of the Istituto Nazionale dei Tumori 
and the Ospedale Niguarda Ca’ Granda of Milan 
were prospectively collected and entered in a master 
database. Patients with extrahepatic disease at 
8195 September 28, 2016|Volume 22|Issue 36|WJG|www.wjgnet.com
Sposito C et al . Prognostic scoring system for resectable HCC
diagnosis and patients who were censored within two 
months were excluded from the present study. The 
master database contained 138 variables, including 
demographic, clinical, laboratory, treatment and survival 
data of each patient. The data were retrieved from the 
database for the purpose of this study after approval 
from the local institutional review boards.
Criteria for diagnosis and indication for LR
Criteria for HCC diagnosis were in accordance with 
EASL/AASLD guidelines evolution[4,5,15]. The diagnosis 
of HCC was made on sequential contrast­enhanced 
imaging studies [chest computed tomography (CT), 
magnetic resonance imaging (MRI), or ultrasound] 
unless one study conclusively demonstrated a tumor 
with arterial enhancement and venous washout. 
In cases lacking conclusive radiological diagnosis, 
ultrasound­guided biopsy was used in both centers.
LR was performed within conventional guidelines 
but also beyond EASL/AASLD recommendations in all 
patients in whom surgical tumor removal was possible 
with a risk/benefit ratio in favor of surgical indication 
when compared with other available options such as 
liver transplantation, loco­regional therapies (ablation, 
transarterial chemoembolization or radioembolization) 
or systemic therapies (Sorafenib). Indication for 
surgery was always discussed in a multidisciplinary 
HCC board with hepatologists, oncologists, radiologists 
and surgeons.
Preoperative workup and definitions
No neoadjuvant locoregional/systemic treatments were 
indicated before surgery. Chest CT scan and contrast­
enhanced abdominal CT scan or MRI were used for 
preoperative staging and volume assessment. The day 
before surgery, a thorough physical examination was 
accomplished, together with a complete biochemistry 
panel including serum alpha­fetoprotein (AFP) levels, 
and an indocyanine green retention test at 15 min. 
Liver function and reserve were determined according 
to the Child­Turcotte­Pugh (CTP) and Model for End­
stage Liver Disease (MELD) scores. Presence of 
clinically relevant portal hypertension was defined as 
the presence of esophageal or gastric varices detectable 
at endoscopy or splenomegaly (major diameter > 12 
cm) with a platelet count < 100000/mm3[5]. Minor hepa­
tectomy was defined as the resection of ≤ 2 adjacent 
liver segments[16].
Perioperative management
All patients received low­molecular weight heparin the 
day before surgery and 2 g of cefazolin 30 min before 
skin incision. After accessing the peritoneal cavity, 
patients underwent complete abdominal exploration. 
Intra­operative ultrasound was used to assess tumor 
characteristics, exclude the presence of adjunctive focal 
lesions in the liver, ascertain intrahepatic vascular and 
biliary anatomy, individualize the resection plane with 
a tumor­free margin of at least 1 cm and eventually 
decide on resectability. Anatomical resection was 
always attempted although the final decision on it was 
strictly dependent on the patient’s tumor and liver 
conditions. Surgery was always performed within a 
fluid minimization protocol, particularly during hepatic 
dissection; a central venous pressure lower than 5 
mm/Hg was targeted.
Follow-up schedule
After hospital discharge, patient follow­up was performed 
in a dedicated liver cancer clinic with hepatological and 
surgical competences in place to treat the underlying 
liver diseases and detect possible recurrence of HCC. 
Physical examination, biochemistry with AFP level 
measurement, chest CT scan and contrast­enhanced 
abdominal CT scan or MRI were performed every 4 mo 
for the first two years and every 6 mo thereafter. Anti-
cancer treatment was not applied until recurrence. 
When recurrence was noted, each patient was treated 
according to disease presentation.
Statistical analysis
Categorical variables were reported as the number 
of cases and percentage; continuous variables were 
expressed as median and interquartile range (IQR). 
OS was estimated by the Kaplan­Meier method and 
calculated from the time from the date of hepatic 
resection to the earliest of death or last follow­up 
evaluation. For patients who underwent liver transplant 
(LT) either for HCC recurrence or end­stage liver 
disease, survival was censored the day before LT.
All eligible patients were randomly allocated into 
a training set or a test set in an approximately 1:1 
ratio with seed set (16438) to make the procedure 
reproducible. For all subjects an independent uniform 
variable was generated and rounded to the closest 
integer: Two groups were identified according to the 
0/1 result. The characteristics of patients in the training 
and test sets were compared using the Pearson chi­
square test (or Fisher exact test, if necessary) for 
categorical variables, the Student t­test for continuous 
variables and the log­rank test for time­to­event data. 
In the training set a Cox proportional hazards 
regression model was used to identify the baseline 
preoperative characteristics predicting OS, and those 
variables identified as significant in the univariate 
analysis at the level of P < 0.05 were tested in the 
multivariable setting. The proportionality assumption 
was verified by Schoenfeld residual analysis. A 
prognostic score was then derived using the inde­
pendent variables weighed according to the estimated 
β regression coefficient of the final Cox model. The 
risk estimate associated with each point was then 
calculated using the Cox proportional hazards model 
according to the formula:
Three prognostic stages (low risk, medium risk 
8196 September 28, 2016|Volume 22|Issue 36|WJG|www.wjgnet.com
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(IQR: 61­73 years). The majority of patients were 
men (705 subjects, 76.9%) and were predominantly 
classified as “fully active” (ECOG PS 0, 93.5%). Eight-
hundred fifty­three patients (93.1%) had CTP grade 
A liver function, and 616 patients (72.1%) had MELD 
score less than or equal to 9[19]. In the majority of 
cases (46.2%), HCV was the etiology of liver disease 
and 320 patients (35%) had clinically relevant portal 
hypertension. Two­hundred sixty­seven patients 
(29.1%) had a tumor size greater than 5 cm and 897 
subjects (97.8%) had up to three tumor nodules. 
Portal invasion was detected in 36 patients (3.9%). 
Thirty­ and ninety­day mortality rates were 1.1% and 
3.5%. Median follow­up of the entire series was 58.1 
mo (95%CI: 52.3­63.9). During follow­up 442 deaths 
were registered. Survival at 5 and 10 years and median 
survival were 49.3%, 26.2% and 58.7 mo (95%CI: 
51.5­65.9) respectively. Recurrence­free survival (RFS) 
at 3 and 5 years and median RFS were 43.7%, 31.8% 
and 28.8 mo (95%CI: 25.0­35.6) respectively.
Among the 917 patients, 480 (52.34%) and 437 
(47.66%) were assigned randomly to the training set 
and the validation set, respectively. The demographic, 
clinical and laboratory characteristics of patients assigned 
in the two sets are presented in Table 1. Overall, the 
patients in the training and the validation sets shared 
and high risk of death at 5 years from surgery) were 
identified according to the changes in the risk estimates 
for each point increase of the score. OS curves in the 
training and test sets for the three prognostic stages 
were obtained with the Kaplan­Meier method and 
compared by means of log­rank test.
Patients in the “low-risk” category were considered 
as “optimal candidates for surgery” according to the 
model’s predicted survival; the dichotomization of the 
model (optimal vs non­optimal candidate for surgery) 
was then compared with the EASL/AASLD indications 
through calculation of Akaike Information Criteria[17], 
comparison of Harrell’s C statistics[18] and comparison 
of survival rates at 5 years.
All analyses were 2­tailed and the threshold of 
significance was assessed at P < 0.05. The statistical 
analysis was performed using STATA®, version 13 
(StataCorp LP, United States). The statistical methods 
of this study were reviewed by Dr. Federica Brunero, 
Clinical Trial Office and Biomedical Statistic, Fondazione 
IRCCS Istituto Nazionale Tumori, Milan, Italy.
RESULTS
A total of 917 eligible adult HCC patients were included. 
Overall, the median age at presentation was 67 years 
Table 1  Baseline patients’ characteristics and comparison between the training and validation sets n  (%)
Training set (n  = 480) Validation set (n  = 437) P  value
Age (yr) 67 (61-73) 68 (61-73) 0.684
Gender, male 374 (77.9) 331 (75.7) 0.436
ECOG PS 0.362
   0 452 (94.2) 405 (92.7)
  1-2 28 (5.8) 32 (7.3)
Child-Pugh 0.118
   A 453 (94.4) 401 (91.8)
   B 27 (5.6) 36 (8.2)
MELD score 8 (7-10) 8 (7-10) 0.791
Etiology 0.516
   Cryptogenic 104 (21.7) 88 (20.1)
   HBV only 94 (19.6) 71 (16.2)
   HCV only 222 (46.25) 217 (49.7)
   Alcohol 48 (10.0) 45 (10.3)
   HBV + HCV 12 (2.5) 16 (3.7)
HCV infection 247 (51.5) 246 (56.3) 0.142
Portal hypertension 165 (34.4) 155 (35.5) 0.728
Platelet count (103/µL) 157 (25-505) 154 (26-914) 0.779
AFP, ng/mL (n = 663) 14.3 (4.7-121.5) 11.4 (4.3-71) 0.160
ICG-R15 (n = 400) 15 (6.1-25) 16 (7.7-22.3) 0.424
Total bilirubin (≥ 1.2 mg/dL) 148 (30.8) 126 (28.8) 0.509
Number of lesions (> 3) 10 (2.1) 10 (2.3) 0.832
Largest diameter (> 5 cm) 143 (29.8) 124 (28.4) 0.637
Portal invasion 22 (4.6) 14 (3.2) 0.283
Extent of hepatectomy (major) 85 (17.7) 78 (17.8) 0.956
Follow-up status (dead) 240 (50.0) 202 (46.2) 0.253
Follow-up time (mo) 35.9 (16.3-61.0) 32.5 (16.7-55.8) 0.254
Overall survival 59.3 (50.2-66.6) 56.4 (47.0-75.8) 0.833
Continuous variables are reported as median values and interquartile range, categorical variables as the number of cases and percentage. Patients’ 
characteristics in the two sets are compared using the Pearson χ 2 test (or Fisher exact test, if necessary) for categorical variables, the Student t-test for 
continuous variables and the log-rank test for time-to-event data. ECOG PS: Eastern Cooperative Oncology Group Performance Status; MELD: Model for 
End-stage Liver Disease; AFP: α-fetoprotein; ICG-R15: Indocyanine green retention test at 15 min.
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similar characteristics, including survival and censoring 
pattern. Greater than 50% of patients presented with 
an active HCV infection. Because HCV infection was the 
prevalent aetiology of cirrhosis, we chose to compare it 
with all the other aetiologies grouped.
Development of the prognostic classification score
Results of the univariate analysis on preoperative 
characteristics are presented in Supplementary Table 
1. Those preoperative variables identified as signi­
ficant in the univariate analysis at the level of P < 
0.05 were fitted in a multivariable Cox proportional 
hazards regression model within the training set. 
The proportionality of hazard ratios for all levels of all 
prognostic factors was verified. The beta coefficients 
were transformed into relative points and a point 
system was constructed according to the method 
described by Sullivan et al[20] (Table 2).
The total score ranged between 0 and 9. The risk 
estimates were calculated for each score using the Cox 
proportional hazards model, and three risk stages were 
defined according to changes in the risk estimates for 
each point increase (Figure 1): Low risk: 0 to 1 points 
Intermediate risk: 2 points; High risk: 3 to 9 points.
OS curves for the three prognostic stages are 
presented in Figure 2. In the training set, a significant 
difference in survival between the three stages was 
demonstrated (χ 2 = 33.56 and P < 0.000), and this 
finding was confirmed in the validation set (χ2 = 23.67 
and P = 0.0002). When considering the case series 
as a whole, 5­year, 10­year and median survival were 
57.2%, 31.2% and 77.2 mo (95%CI: 67.4­87.0) 
respectively in the low risk category, 40.3% 22.6% 
and 41.7 mo (95%CI: 34.7­48.7) respectively in the 
intermediate category and 22.3% 13.4% and 17.4 
mo (95%CI: 10.1­24.6) respectively in the high risk 
category (P < 0.000). Three­year, 5­year and median 
RFS were 46.4%, 33.8% and 31.5 mo (95%CI: 
25.3­35.7) respectively in the low risk category, 40.1% 
28.1% and 29.9 mo (95%CI: 25.6­34.2) respectively 
in the intermediate category and 34.5% 25.9% and 
12.5 mo (95%CI: 2.8­22.2) respectively in the high 
risk category (P = 0.020). Details on sites of HCC 
recurrence and treatments for recurrence are shown in 
supplementary Table 2.
Identification of the ideal candidates for surgery and 
comparison with the EASL/AASLD guidelines
Patients in the low­risk category were considered as 
ideal candidates for LR according to the predicted 
survival. This criterion allowed the inclusion of 314 
patients considered non­ideal candidates according to 
EASL/AASLD guidelines.
Overall, 593 patients (69.4% of the total of 854 
evaluable patients according to both classifications) 
were ideal candidates for LR according to the proposed 
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Figure 1  Scoring system according to risk estimates of death at 5-yr. Patients are considered at low risk with a score = 0-1 (risk estimates: 0.347-0.459), 
intermediate risk with a score = 2 (risk estimate: 0.59), and high risk with a score = 3-9 (risk estimates: 0.723-1).
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Table 2  Multivariable Cox proportional hazards regression 
model (training set) and relative point system
Variable HR 95%CI P  value β Points
MELD score ≤ 9 0
MELD score > 9 1.444 (1.080-1.931)   0.013 0.3674 1
HCV infection absent 0
HCV infection present 1.468 (1.112-1.937)    0.007 0.3839 1
Number of lesions ≤ 3 0
Number of lesions > 3 3.253 (1.434-7.380)    0.005 1.1795 3
Largest diameter ≤ 5 cm 0
Largest diameter > 5 cm 1.459 (1.085-1.963)    0.012 0.3779 1
Portal invasion absent 0
Portal invasion present 3.500 (2.016-6.073) < 0.001 1.2526 3
MELD: End-stage Liver Disease; HCV: Hepatitis C virus.
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Figure 2  Kaplan-Meier survival estimates for the risk classes in the training set (A) and the test set (B).
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Milan score, whereas only 323 patients were ideal 
candidates for LR according to the EASL/AASLD 
guidelines (37.8% of the total). This finding resulted 
in a net increase of 31.6% of patients with ideal 
indication for LR.
Comparison with the EASL/AASLD surgical guid­
elines was performed by means of AIC, Harrell’s C 
statistics and 5­year survival rates. AIC for EASL/
AASLD surgical guidelines was 5323.259 and AIC for 
the Milan score was 4683.745. Harrell’s C was 0.5971 
and 0.5849 for the EASL/AASLD surgical guidelines 
and the proposed criteria respectively (P = 0.617), 
showing that there is no evidence that the two systems 
have different predictive power.
The 5­year survival rates for patients who are ideal 
candidates for surgery according to the two systems 
were not significantly different (z = -1.6022, P = 0.06), 
and median survivals did not differ (z = ­0.789, P = 
0.22) (Table 3).
DISCUSSION
LR still represents the cornerstone for any curability 
attempt in patients with HCC. A large burden of 
surgical literature has challenged the current Western 
guidelines. However, LR for HCC is recommended 
only for single nodules of any size in patients without 
tumor related symptoms, no clinically significant portal 
hypertension and normal bilirubin[4,5]. If this profile is 
not fulfilled, postoperative morbidity may increase, 
and long­term survival may be significantly reduced. 
In contrast, when patients meet these criteria, long­
term survival may equate that of LT. Thus, LR under 
restricted conditions maintains its role as a first­line 
therapeutic option in patients with early HCC[7]. The 
restrictive approach indicated by Western guidelines 
was established more than 15 years ago[21], and its 
conservative recommendations for surgical indications 
have not evolved over time despite the significant 
improvement in surgical techniques and technologies 
and their reflections on patient outcomes. An extension 
of the recommendations has been repeatedly 
suggested given that resection can be attempted 
with high rates of technical success and acceptable 
survival rates in patients with clinically significant portal 
hypertension[22], multiple nodules[10] or intrahepatic 
vascular invasion[9]. In this context, it is not surprising 
to observe that experienced surgical centres both in 
the East and in the West adopt a more liberal approach 
to LR in HCC that does not strictly follow the guidelines. 
In a recent large multicentre series of patients resected 
for HCC, less than 30% of cases were considered as 
ideal candidates for resection according to the current 
guidelines[12].
In this study, we retrospectively analyzed a large 
series of approximately 1000 HCC patients who 
underwent LR at two hospitals in Milan (Italy) with 
large volumes of activity. Both centres offered LR even 
outside the current EASL/AASLD guidelines, and indeed 
greater than 60% of patients were considered as non­
ideal candidates for LR. At baseline, patients presented 
with clinically relevant portal hypertension and/or 
abnormal bilirubin in greater than 30% of cases and 
had multifocal tumors in greater than 20% of cases. In 
addition, the maximum tumor size was larger than 5 
cm in greater than 30% of cases. The low perioperative 
mortality of 3.5% observed at 3 mo and the long follow­
up of nearly 60 mo allowed a thorough analysis of those 
preoperative factors that independently influenced the 
long­term survival of these patients. To reduce the bias 
deriving from the absence of an external validation 
cohort, the case series was randomly divided into a 
training set and a validation set. We then performed 
the uni­ and multivariable analysis on the training 
set. As expected, the independent variables related to 
survival were liver related (MELD score > 9, presence 
of active HCV infection) and tumor related (number 
of nodules > 3, the largest diameter of nodules > 5 
cm and presence of portal invasion). Interestingly, 
as previously observed[22], clinically relevant portal 
hypertension did not independently affect survival. The 
same occurred for bilirubin above normal levels, which 
was not independently associated with survival when a 
composite score, such as MELD, was introduced in the 
multivariable analysis.
According to the weight of each factor inde­
pendently related with survival and the corresponding 
risk estimates, an easy­to­determine prognostic 
scoring system was built. Then, according to changes 
in the risk estimates for each point increase, a 
stratification in three prognostic strata was computed: 
low (0­1 points), intermediate (2 points) and high (3­9 
points) risk population. The corresponding median 
survivals were 77.2 mo (95%CI: 67.4­87.0), 41.7 mo 
(95%CI: 34.7­48.7) and 17.4 mo (95%CI: 10.1­24.6), 
respectively (P < 0.0001). The significant difference 
No. Of patients (%) Median OS (95%CI) 5-yr OS 10-yr OS
EASL/AASLD Ideal 323 (37.8)   83 (73-108) 64.4 37.0
Non-ideal 531 (62.2) 46 (41-52) 42.0 21.2
Current study Ideal 593 (69.4) 77 (64-44) 57.2 31.2
Non-ideal 261 (30.6) 38 (30-44) 35.8 20.0
EASL: European Association for the Study of the Liver; AASLD: American Association for the Study of Liver Diseases.
Table 3  Median overall survival and 1- 3- and 5-year survival probabilities for ideal and non-
ideal candidates for liver resection according to European Association for the Study of the Liver/
American Association for the Study of Liver Diseases and the current study
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in survival, overall and between strata, was confirmed 
also in the validation set and the entire cohort. This 
scoring system allows prospecting the post­surgical 
outcomes by assessing five easily accessible chara­
cteristics and thus may help clinicians when selecting 
between different treatment options for HCC patients.
Patients in the low­risk category were considered 
as ideal candidates for LR according to the observed 
survival of approximately 60% at 5 years, which 
approximates that of patients undergoing LT for HCC. 
This finding allowed to consider 593 patients (69.4% of 
the total of 854 evaluable patients) as “ideal candidates” 
for resection with respect to patients who would have 
been considered as “ideal candidates” according to 
EASL/AASLD guidelines (less than 40% patients) and 
resulted in a net increase of 31.6% of patients with 
indication for LR. The predictive power of the proposed 
criteria in the identification of the ideal candidate for 
resection was similar to that of the current guidelines in 
terms of AIC and Harrel’s C statistics. Most importantly, 
inclusion of a significantly increased number of patients 
in the definition of “ideal candidates” did not result in a 
significant decrease in terms of survival. After all, the 
proposed score broadens and enhances the concept 
of “surgical HCC” that is often discarded in the hepato-
oncology community due to an insufficient definition 
and poor evidence.
There are some limitations of this study. Firstly, 
despite prospective data collection, this is a retros­
pective study performed in only two high­volume 
centres. An external validation in a different population 
is required to strengthen the study results. Secondly, 
a different method of defining the training set could 
have been chosen, e.g., the bootstrapping method, 
although the presented sample size was sufficiently 
large to meet generalizability criteria. Thirdly, active 
HCV infection was identified as an independent 
prognostic factor in this series, and this result may not 
totally apply in other settings where other aetiologies 
of cirrhosis are prevalent. In this respect, the recent 
introduction of direct antiviral agents to treat HCV 
infection may reveal other factors with a significant 
weight on patients’ prognosis in the future. Finally, 
this study included only patients who underwent open 
LRs. Some factors, particularly those related to liver 
function, may have less significant impacts on long­
term outcomes for patients undergoing laparoscopic 
LR[23].
In conclusion, this study provides an easily accessible 
tool to stratify the prognosis of patients undergoing 
LR for HCC. The identified subset of patients at low 
risk could enter the group of ideal candidates for LR 
given that their prognosis approaches that of patients 
undergoing LT for HCC. The proposed criteria may 
expand safely the current EASL/AASLD indications for 
LR with no detrimental effect on patient prognosis.
COMMENTS
Background
The prognosis of patients with hepatocellular carcinoma (HCC) largely depends 
on tumor extension and underlying liver function. According to Western 
Guidelines, liver resection (LR) is considered as the first-line treatment only 
for a restricted subset of patients with an optimal liver function, a preserved 
physical condition and a single tumor nodule with no evidence of extra-hepatic 
spread or involvement of major vascular structures. If this profile is fulfilled, 
postoperative morbidity is low and long-term survival may equate that of liver 
transplantation.
Research frontiers
Several field practice studies have ascertained that LR is often offered 
outside Western guidelines, and various authors reported acceptable survival 
rates for patients with HCC resected at a more advanced stage because of 
macrovascular invasion, multiple nodules or impaired liver function. In addition, 
more recent studies demonstrate a survival benefit of radical surgery with 
respect to the available treatment alternatives across the different Barcelona 
Clinic Liver Cancer staging system stages.
Innovations and breakthroughs
The authors analyzed a large consecutive series of patients who underwent LR 
for HCC at two Italian centres, of whom greater than 60% of cases were outside 
Western guidelines. Five variables were identified as independently related 
to survival: Model for End-stage Liver Disease score > 9, presence of active 
hepatitis C virus infection, number of nodules > 3, largest diameter of nodules > 
5 cm and presence of portal invasion. According to the weight of each variable, 
an easy-to-determine prognostic scoring system was built that allowed the 
identification of three risk strata with significantly different survival rates. Overall 
survival of patients in the low-risk strata was similar to that of patients who 
underwent LR according to Western guidelines. Considering LR patients in the 
low-risk strata as “ideal candidates” allowed a net increase of 31.6% of patients 
with indication for LR with respect to Western guidelines.
Applications
This scoring system allows assessment of the post-surgical outcomes by 
assessing five easily accessible characteristics and thus may help clinicians 
when selecting between different treatment options for HCC patients. Inclusion 
of a significantly higher number of patients in the definition of “ideal candidates” 
did not result in a significant decrease in terms of survival. Thus, the proposed 
score may broaden and enhance the concept of “surgical HCC” that is often 
discarded in the hepato-oncology community due to an insufficient definition 
and poor evidence.
Terminology
Ideal candidates for LR according to Western guidelines are defined by 
an optimal liver function (Child-Pugh A, normal bilirubin and absence of 
clinically relevant portal hypertension), a preserved physical condition (ECOG 
Performance Status of 0), and a single tumor nodule with no evidence of extra-
hepatic spread or involvement of major vascular structures.
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